Vogt-Koyanagi-Harada disease occurring during interferon alpha therapy for chronic hepatitis C. 2004

Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
Department of General Medicine, Osaka University Graduate School of Medicine, 2-15 Yamada-Oka, 565-0871, Suita, Japan.

Retinal abnormalities, including retinal hemorrhage and "cotton-wool" spots, often occur within the first 8 weeks in the course of interferon therapy in patients with chronic hepatitis C. Here, we describe a case of Vogt-Koyanagi-Harada disease occurring 4 months after the start of interferon alpha treatment, probably induced by the immunomodulatory effects of interferon. Therefore, we conclude that chronic hepatitis C patients, especially people with darkly pigmented skin, need to be closely monitored for ophthalmologic complications, by periodic check-up of the optic fundi, for a prolonged period, during interferon treatment.

UI MeSH Term Description Entries
D008297 Male Males
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012880 Skin Pigmentation Coloration of the skin. Skin Color,Skin Tone,Color, Skin,Colors, Skin,Pigmentation, Skin,Pigmentations, Skin,Skin Colors,Skin Pigmentations,Skin Tones,Tone, Skin,Tones, Skin
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014607 Uveomeningoencephalitic Syndrome A syndrome characterized by bilateral granulomatous UVEITIS with IRITIS and secondary GLAUCOMA, premature ALOPECIA, symmetrical VITILIGO, poliosis circumscripta (a strand of depigmented hair), HEARING DISORDERS, and meningeal signs (neck stiffness and headache). Examination of the cerebrospinal fluid reveals a pattern consistent with MENINGITIS, ASEPTIC. (Adams et al., Principles of Neurology, 6th ed, p748; Surv Ophthalmol 1995 Jan;39(4):265-292) Uveomeningoencephalitis,Vogt-Koyanagi-Harada Syndrome,Syndrome, VKH (Vogt Koyanagi Harada),Syndrome, Vogt Koyanagi Harada,VKH (Vogt Koyanagi Harada) Syndrome,VKH Syndrome,Vogt-Koyanagi-Harada Disease,Disease, Vogt-Koyanagi-Harada,Syndrome, Uveomeningoencephalitic,Syndrome, VKH,Syndrome, Vogt-Koyanagi-Harada,Uveomeningoencephalitides,VKH Syndrome (Vogt Koyanagi Harada),Vogt Koyanagi Harada Disease,Vogt Koyanagi Harada Syndrome
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon

Related Publications

Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
October 2010, International ophthalmology,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
March 2011, The Korean journal of hepatology,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
March 2010, Journal francais d'ophtalmologie,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
February 2006, The Journal of infection,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
November 2005, American journal of ophthalmology,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
November 2003, Journal of viral hepatitis,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
January 2011, Case reports in ophthalmology,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
January 1995, The British journal of ophthalmology,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
January 2020, Middle East African journal of ophthalmology,
Akinori Kasahara, and Atsushi Hiraide, and Naruya Tomita, and Hiromi Iwahashi, and Akihisa Imagawa, and Nobuyuki Ohguro, and Shuji Yamamoto, and Eiji Mita, and Norio Hayashi
November 2015, Current opinion in ophthalmology,
Copied contents to your clipboard!